| Literature DB >> 20711476 |
Gerald P Douglas1, Oliver J Gadabu, Sabine Joukes, Soyapi Mumba, Michael V McKay, Anne Ben-Smith, Andreas Jahn, Erik J Schouten, Zach Landis Lewis, Joep J van Oosterhout, Theresa J Allain, Rony Zachariah, Selma D Berger, Anthony D Harries, Frank Chimbwandira.
Abstract
Entities:
Mesh:
Substances:
Year: 2010 PMID: 20711476 PMCID: PMC2919419 DOI: 10.1371/journal.pmed.1000319
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Figure 1ART Clinic filing room at Queen Elizabeth Central Hospital.
The man pictured in Figure 1 has given written informed consent (as outlined in the PLoS consent form) allowing the publication of his photograph. Image credit: Joep J. van Oosterhout.
Characteristics and Treatment Outcomes of ART Patients Registered at the Six EMR Sites in Malawi up to December 31, 2009.
|
| Patients registered for ART | 42,834 | |
| Patients transferred in on ART | 5,943 (14) | ||
| Patients newly initiated on ART | 36,891 (86) | ||
| Males (%) (all ages) | 17,770 (41) | ||
| Non-pregnant females (all ages) | 22,575 (53) | ||
| Pregnant females (%) (all ages) | 2,489 (6) | ||
| Adults (%) (15 years or older at ART initiation) | 39,165 (91) | ||
| Children (%) (18 months–14 years at ART initiation) | 3,241 (8) | ||
| Infants (%) (0–17 months at ART initiation) | 428 (1) | ||
| Number (%) on ART due to: | |||
| Presumed severe HIV disease in infants | 31 (0) | ||
| Confirmed HIV infection in infants (PCR) | 21 (0) | ||
| WHO stage 1 or 2, CD4 below threshold | 11,093 (26) | ||
| WHO stage 2, total lymphocytes <1,200/mm3 | 0 (0) | ||
| WHO stage 3 | 23,954 (56) | ||
| WHO stage 4 | 7,090 (17) | ||
| Unknown/other reason outside guidelines | 645 (2) | ||
| Number (%) on ART due to: | |||
| TB (%) (any form, history of TB, or current TB) | 7,381 (17) | ||
| Kaposi's sarcoma | 2,120 (5) | ||
|
| Number (%) alive and on ART | 24,524 (57) | |
| Number (%) died | 3,953 (9) | ||
| Number (%) dying in first month | 1,012 (2) | ||
| Number (%) dying in second month | 773 (2) | ||
| Number (%) dying in third month | 414 (1) | ||
| Number (%) dying after third month | 1,754 (4) | ||
| Number (%) defaulted (>2 months after ARVs finished) | 5,679 (13) | ||
| Number (%) stopped treatment | 362 (1) | ||
| Number (%) transferred out | 7,961 (19) | ||
| Number (%) unknown outcome (pre-EMR, files lost) | 355 (1) | ||
| Of those alive and on ART: | |||
| 1st line (start) | d4T 3TC NVP | 21,943 (89) | |
| 1st line alternatives | AZT 3TC NVP | 1,377 (6) | |
| d4T 3TC EFV | 649 (3) | ||
| AZT 3TC EFV | 150 (1) | ||
| 2nd line adult | AZT 3TC TDF LPV/r | 299 (1) | |
| 2nd line child | ddl ABC LPV/r | 17 (0) | |
| Non-standard regimen | Any other regimen | 89 (0) | |
| Of those alive and on ART: | |||
| Number (%) with side effects | 1,023 (4) | ||
| Number where pill counts were done in last month of quarter | 21,284 | ||
| Number (%) with pill count in last month of quarter ≤8 | 21,064 (99) | ||
| Number (%) adherent | 17,368 (82) | ||
To produce these data manually can take up to 5 days per site, and may involve clinic closure to allow staff to clean data and compile reports. Using reporting tools built into the EMR, cohort reports can be produced in just a few minutes.
ABC, abacavir; AZT, zidovudine; ddI, didanosine; D4T, stavudine; EFV, efavirenz; LPV/r, lopinavir/ritonavir; NVP, nevirapine; PCR, polymerase chain reaction; TB, tuberculosis; 3TC, lamivudine.